Physical and mental health of long-term users of HIV pre-exposure prophylaxis (PrEP) in Australia: The X-PLORE Cohort
AIDS. 2023 Oct 23. doi: 10.1097/QAD.0000000000003768. Online ahead of print.
ABSTRACT
INTRODUCTION: HIV pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV. We aimed to assess mental and physical health among long-term PrEP users in Australia’s X-PLORE cohort.
METHODS: In early 2021, 1,485 X-PLORE participants were emailed a survey covering demographics, sexual practices, ongoing PrEP use, physical and psychological diagnoses received since commencing PrEP, substance use, and impacts of the COVID-19 pandemic. Current anxiety and depression were assessed using GAD-7 and PHQ-9 questionnaires.
RESULTS: Of 476 participants (completion rate 32.1%), 99.8% were cis-gender men. Median PrEP use duration was 48 months (2,002 person-years), with 81.7% currently using PrEP. PrEP-related toxicity was uncommon: 2.9% reported bone fractures, 1.3% low bone density, and 4.0% reported kidney problems, largely not necessitating PrEP cessation. Most (92.0%) rated their health as “good” to “excellent”, and 22.6% reported improved health since starting PrEP, often due to improved mental health. Only 6.2% reported deterioration in health since starting PrEP, largely unrelated to PrEP. The most common diagnoses were hypertension (9.9%), depression (13.2%) and anxiety (14.9%); 17.0% had PHQ-9 scores indicating current moderate-to-severe depression, which was associated with unemployment (aOR 3.90), regular cannabis use (aOR 2.49), and having ceased PrEP (aOR 2.13).
CONCLUSIONS: Among long-term PrEP users, of which over 80% were currently using PrEP, self-reported PrEP toxicity was uncommon. With almost one in five PrEP users categorised as having depression, and with higher risk among those having ceased PrEP, we recommend routine screening for depression and anxiety in PrEP users and corresponding follow-up of patients no longer attending for PrEP.
PMID:37877295 | DOI:10.1097/QAD.0000000000003768